Vazkepa is indicated to reduce the risk of cardiovascular events in adult statin-treated patients at highcardiovascular risk with elevated triglycerides (≥ 150 mg/dL [≥ 1.7 mmol/L]) and• established cardiovascular disease, or• diabetes, and at least one other cardiovascular risk factor.